Intracellular stability of anti-caspase-3 intrabodies determines efficacy in retargeting the antigen.

J Biol Chem

Pfizer Central Research, Groton, Connecticut 06340, USA.

Published: August 2001

Although intracellular antibodies (intrabodies) are being explored as putative therapeutic and research reagents, little is known about the principles that dictate the efficacy of these molecules. In our efforts to address this issue, we generated a panel of five intrabodies, directed against catalytically inactive murine caspase-3, by screening single-chain antibody (Fv) phage display libraries. Here we determined criteria that single-chain Fv fragments must fulfill to act as efficient intrabodies. The affinities of these intrabodies, as measured by surface plasmon resonance, varied approximately 5-fold (50-250 nm). Despite their substantial sequence similarity, only two of the five intrabodies were able to significantly accumulate intracellularly. These disparities in intracellular expression levels were reflected by differences in the stability of the purified protein species when analyzed by urea denaturation studies. We observed varied efficiencies in retargeting the antigen murine caspase-3, from the cytosol to the nucleus, mediated by intrabodies tagged with an SV40 nuclear localization signal. Our results demonstrate that the intrinsic stability of the intrabody, rather than its affinity for the antigen, dictates its intracellular efficacy.

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M101332200DOI Listing

Publication Analysis

Top Keywords

retargeting antigen
8
murine caspase-3
8
intrabodies
7
intracellular
4
intracellular stability
4
stability anti-caspase-3
4
anti-caspase-3 intrabodies
4
intrabodies determines
4
determines efficacy
4
efficacy retargeting
4

Similar Publications

Achieving the precise targeting of lentiviral vectors (LVs) to specific cell populations is crucial for effective gene therapy, particularly in cancer treatment where the modulation of the tumor microenvironment can enhance anti-tumor immunity. Programmed cell death protein 1 (PD-1) is overexpressed on activated tumor-infiltrating T lymphocytes, including regulatory T cells that suppress immune responses via FOXP3 expression. We developed PD1-targeted LVs by incorporating the anti-PD1 nanobody nb102c3 into receptor-blinded measles virus H and VSV-G glycoproteins.

View Article and Find Full Text PDF

Background: Pancreatic ductal adenocarcinoma (PDAC) represent an unmet clinical need. Approximately 90% of PDACs express high levels of αvβ6 integrin. We have previously described Ad5-A20, an adenovirus vector with ablated native means of cell entry and retargeted to αvβ6 integrin by incorporation of an A20 peptide.

View Article and Find Full Text PDF

Hepatitis B virus enhancer 1 activates preS1 and preS2 promoters of integrated HBV DNA impairing HBsAg secretion.

JHEP Rep

September 2024

Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University, Beijing, China.

Article Synopsis
  • The study investigates how the expression and secretion of HBsAg from integrated HBV DNA affect the ability to achieve a functional cure for chronic hepatitis B.
  • It analyzes liver biopsy samples from 625 patients, including treatment-naive and functionally cured individuals, to compare HBsAg levels and explore the mechanisms behind HBsAg secretion differences in HBeAg-positive versus negative patients.
  • Results show that HBeAg-negative patients have lower serum HBsAg but similar intrahepatic levels, with impaired secretion linked to an increase in preS1 mRNA from integrated HBV DNA, disrupting the balance in transcriptional activity of related promoters.
View Article and Find Full Text PDF

The Immunotherapy of Acute Myeloid Leukemia: A Clinical Point of View.

Cancers (Basel)

June 2024

Hematology and Bone Marrow Transplantation Unit (BMTU), Hospital of Bolzano (SABES-ASDAA), Teaching Hospital of Paracelsus Medical University (PMU), 39100 Bolzano, Italy.

The potential of the immune system to eradicate leukemic cells has been consistently demonstrated by the vs. effect occurring after allo-HSCT and in the context of donor leukocyte infusions. Various immunotherapeutic approaches, ranging from the use of antibodies, antibody-drug conjugates, bispecific T-cell engagers, chimeric antigen receptor (CAR) T-cells, and therapeutic infusions of NK cells, are thus currently being tested with promising, yet conflicting, results.

View Article and Find Full Text PDF
Article Synopsis
  • T-cell engaging (TCE) bispecific antibodies can effectively target and eliminate cancer cells by activating T cells, but their use is limited by potential toxic side effects that can affect healthy cells as well.
  • The study introduces a novel strategy using pro-drug forms of TCEs that become active specifically in the tumor environment by incorporating a masking approach that relies on tumor-enriched proteases.
  • Researchers successfully engineered and tested a pro-drug TCE using the anti-CD3 antibody E10, demonstrating its ability to activate T cells selectively within tumors, highlighting a promising avenue for safer cancer immunotherapy.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!